Imidazole derivatives used as tafia inhibitors

摘要

Disclosed are amino-pyridinyl imidazole derivatives as represented by the general formula (la), where U is hydrogen, X is -CH2-A2, A2 is optionally substituted aminopyridyl, Y is optionally substituted cycloalkyl, Z is hydrogen, alkyl, alkyl-OH, alkyl-cycloalkyl or alkyl-O-C(O)-O-cycloalkyl, and wherein the other substituents are as defined herein. Also disclosed is the use of a compound as defined above for producing a medicament for the prophylaxis and therapy of all disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes (including disorders such as myocardial infarction, angina pectoris and other types of acute coronary syndrome, stroke, peripheral vascular disorders, deep vein thrombosis, pulmonary embolism, embolic or thrombotic events caused by cardiac arrhythmias, cardiovascular events such as restenosis following revascularization, angioplasty, stent implantations, bypass operations and similar procedures, reduction of the risk of thrombosis following surgical procedures, disseminated intravascular coagulation, sepsis and other intravascular events which are associated with an inflammation, atherosclerosis, diabetes and metabolic syndrome and its squelae, tumor growth and tumor metastasis, impairments of the hemostatic system such as fibrin deposits, fibrotic changes of the lung such as chronic obstructive lung disease, adult respiratory distress syndrome or fibrin deposits in the eye after eye operations or prevention and/or treatment of scar formation).